Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Why Billionaires and Hedge Funds Are Betting Big on China’s Recovery

by Team Lumida
October 2, 2024
in Equities, Macro
Reading Time: 3 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  1. Hedge funds made record purchases of Chinese stocks, betting on Beijing’s stimulus to revive the economy.
  2. Major investors like David Tepper and BlackRock are increasing their stakes in Chinese shares.
  3. Despite the rally, some managers remain cautious, questioning the sustainability of the recovery.

What Happened?

Hedge funds are aggressively buying Chinese stocks, driven by optimism around Beijing’s new stimulus measures aimed at rejuvenating the economy. According to Goldman Sachs, hedge funds made record net purchases of Chinese and Hong Kong stocks in September.

Mount Lucas Management, GAO Capital, and Timefolio Asset Management are leading the charge, investing in Chinese large-cap stocks and exchange-traded funds. Mainland Chinese stocks surged into a bull market, marking the biggest jump since 2008, and Hong Kong-listed stocks followed suit.

Why It Matters?

This influx of investment into Chinese equities signifies a major shift in sentiment. After years of underperformance, Chinese stocks are now attracting significant interest from heavyweight investors like David Tepper and BlackRock, who are increasing their stakes.

According to David Aspell of Mount Lucas, “Stocks often bottom and rally hard before the economy does,” highlighting a potential turnaround. This surge suggests confidence in Beijing’s ability to stabilize the economy through its aggressive stimulus measures. However, some investors remain skeptical, questioning whether the government will maintain its initiatives.

What’s Next?

Investors should closely monitor Beijing’s follow-through on its stimulus promises. The sustainability of this rally will largely depend on continued government support and clarity on international trade relations, especially with the upcoming US presidential election.

While some managers, like Blue Edge Advisors’ Calvin Yeoh, are approaching with caution, others like Nigel Peh of Timefolio Asset Management believe the worst of negative sentiment is over. Watch for potential regulatory changes and economic data that could impact the market’s trajectory.

Source: Bloomberg
Previous Post

Powell Signals Patience: Fed to Lower Rates ‘Over Time’

Next Post

Market Bulls Rejoice: Hong Kong Stocks and Options Align for Gains

Recommended For You

French Yield Premium Hits Euro-Crisis Levels and Italy Spreads Widen Fastest Since March 2020 as EU Officials Warn on Borrowing

by Team Lumida
3 hours ago
JPMorgan Sees Diesel Falling to $4.70 a Gallon Within 15 Days of an Export Ban, Then Reversing as Refiners Cut Runs

Brussels can grant fiscal flexibility but cannot make investors lend, which has shifted the binding constraint from EU rules to bond markets.

Read more

UK Diesel Passes £2 a Litre With Economists Warning of 5.3% Inflation, as the G7 Releases Up to 100 Million Barrels

by Team Lumida
3 hours ago
UK Diesel Passes £2 a Litre With Economists Warning of 5.3% Inflation, as the G7 Releases Up to 100 Million Barrels

Demand barely responds to price, with a 10% rise cutting consumption just 1%, so a supply shock passes almost entirely into costs.

Read more

Tesla Delivers 486,532 Vehicles, Beating Estimates, Helped by Chinese-Built Cars Entering Canada Under a 6.1% Tariff Quota

by Team Lumida
3 hours ago
Tesla Delivers 486,532 Vehicles, Beating Estimates, Helped by Chinese-Built Cars Entering Canada Under a 6.1% Tariff Quota

An American company is supplying the Canadian market from Chinese factories under a Carney-Xi agreement, bypassing the US-Canada trade dispute.

Read more

SEC Censures JPMorgan With No Fine After a Disqualified Trader Handled 800 Swap Transactions Over Two Years

by Team Lumida
5 hours ago
SEC Censures JPMorgan With No Fine After a Disqualified Trader Handled 800 Swap Transactions Over Two Years

The regulator cited self-reporting and remediation in imposing no penalty, a concrete data point on what voluntary disclosure is worth.

Read more

Trump Says Europe Will Release Diesel Immediately, Making a US Export Ban Less Likely as Crude Falls to $89.75

by Team Lumida
5 hours ago
Trump Says Europe Will Release Diesel Immediately, Making a US Export Ban Less Likely as Crude Falls to $89.75

The announcement came via social media with no volumes, no timeline and no European confirmation quoted.

Read more

Novartis Inks Chinese mRNA-Therapy Deal; Abogen Biosciences $7.8B; ABO2203 Autoimmune T-Cell Engager; $575M Upfront; White Blood Cell Depletion; Novo Nordisk Jiangsu Hengrui $2.6B Obesity Pill; AstraZeneca Summit $2B Cancer; Chimagen GSK Blood-Cancer; Big Pharma China Drug Licensing Trend

by Team Lumida
12 hours ago
Novartis Inks Chinese mRNA-Therapy Deal; Abogen Biosciences $7.8B; ABO2203 Autoimmune T-Cell Engager; $575M Upfront; White Blood Cell Depletion; Novo Nordisk Jiangsu Hengrui $2.6B Obesity Pill; AstraZeneca Summit $2B Cancer; Chimagen GSK Blood-Cancer; Big Pharma China Drug Licensing Trend

Novartis AG licensing mRNA-based autoimmune therapy from China's Abogen Biosciences. Deal worth $7.8B (up to $7.2B additional milestones). $575M upfront for mRNA-encoded T-cell engager (ABO2203). Drug resets immune...

Read more

IG Group Holdings Stock Plunges 27%; Q3 Revenue Surprise Slump; £240M Q3 Sales -14% YoY; May Guidance Cut 10-15% to Mid-Single Digit; Over-the-Counter Revenue -18%; Customer Income +8%; Underdog Acquisition $1.3B July; Oct 22 Strategy Update

by Team Lumida
12 hours ago
IG Group Holdings Stock Plunges 27%; Q3 Revenue Surprise Slump; £240M Q3 Sales -14% YoY; May Guidance Cut 10-15% to Mid-Single Digit; Over-the-Counter Revenue -18%; Customer Income +8%; Underdog Acquisition $1.3B July; Oct 22 Strategy Update

IG Group Holdings Plc shares plummeted 27% (steepest intraday decline since Dec 2016). Q3 revenue expected £240M (~$317M)—14% drop vs prior year. Company cut 2026 guidance: expected mid-single...

Read more

Dyson’s $995 Million Dividend Reverses Years of Payouts; £750M Distribution Weybourne Holdings 2025; $19.7B Net Worth (UK #2); £6.1B Revenue -6.7% YoY; Operating Profit +15% £603M; AI Stain-Detection Robot; Singapore Headquarters; Family Office Diversification; Insurance Unit; Farming/Land Expansion; Jane Simpson CIO

by Team Lumida
12 hours ago
Dyson’s $995 Million Dividend Reverses Years of Payouts; £750M Distribution Weybourne Holdings 2025; $19.7B Net Worth (UK #2); £6.1B Revenue -6.7% YoY; Operating Profit +15% £603M; AI Stain-Detection Robot; Singapore Headquarters; Family Office Diversification; Insurance Unit; Farming/Land Expansion; Jane Simpson CIO

James Dyson's vacuum cleaner-maker ramped up annual dividend to billionaire's family holding company. £750M ($995M) distribution 2025 to Singapore-based Weybourne Holdings. Previous dividend 2024: £200M (lowest in 7...

Read more

New World Development Shares Fall Post Loss; HK$28.1B Loss ($3.6B); 11 Skies Exit HK$18.3B Write down; Third Annual Loss; HK$3B Airport Authority Payment; Three Towers/Entertainment Venue April Handover; White-Knight Investor Opportunity; Chow Tai Fook Support; Echo Huang CEO Balance Sheet Optimization; Blackstone Deal Scrapped

by Team Lumida
12 hours ago
New World Development Shares Fall Post Loss; HK$28.1B Loss ($3.6B); 11 Skies Exit HK$18.3B Write down; Third Annual Loss; HK$3B Airport Authority Payment; Three Towers/Entertainment Venue April Handover; White-Knight Investor Opportunity; Chow Tai Fook Support; Echo Huang CEO Balance Sheet Optimization; Blackstone Deal Scrapped

New World Development shares plummeted despite HK$28.1B ($3.6B) loss announcement. Stock jumped 10% early (11 Skies exit positive), fell 4% afternoon (broader Hong Kong selloff). HK$18.3B writedown for...

Read more

Firmus Grid Prices IPO A$11 Share; A$43.7B Valuation ($30.3B); A$5B Raise Australia; Oct 23 ASX Debut; Batam Indonesia Data Center; Nvidia Partnership 8-Year; Jane Street Blackstone Investment; Anthropic Mega IPO Pipeline; Moonshot $5B Hong Kong; Major Australian IPO; Bitcoin Mining 2019

by Team Lumida
12 hours ago
Firmus Grid Prices IPO A$11 Share; A$43.7B Valuation ($30.3B); A$5B Raise Australia; Oct 23 ASX Debut; Batam Indonesia Data Center; Nvidia Partnership 8-Year; Jane Street Blackstone Investment; Anthropic Mega IPO Pipeline; Moonshot $5B Hong Kong; Major Australian IPO; Bitcoin Mining 2019

Firmus Grid Ltd. priced IPO A$11/share; seeking A$5B+ Australian listing Oct 2026. Valuation A$43.7B ($30.3B USD)—below A$50B expectations. Bookbuild Oct 6-9; ASX debut Oct 23. Proceeds fund GPU...

Read more
Next Post

Market Bulls Rejoice: Hong Kong Stocks and Options Align for Gains

Geopolitical Shockwave: U.S. Stocks Fall, Oil Prices Spike After Iran Strikes Israel

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

AI Security Breach: How Hackers Stole OpenAI’s Internal Secrets

Delaware AG Seeks Investment Bank to Advise on OpenAI Restructuring Amid Legal and Regulatory Scrutiny

May 29, 2025
Hedge Funds Hold Record 7% of Treasury Market, Drawing Quiet Fed Scrutiny as Leverage and Basis Trades Mount

Hedge Funds Hold Record 7% of Treasury Market, Drawing Quiet Fed Scrutiny as Leverage and Basis Trades Mount

September 15, 2026
Microsoft’s AI Empire: Nadella’s Bold Moves and Billion-Dollar Bets

Microsoft’s Data-Center Crunch to Persist Into 2026

October 10, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018